文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > CD20-specific adoptive immunotherapy for lymphoma
侵权投诉

CD20-specific adoptive immunotherapy for lymphoma

GENETHERAPY

CD20-speci cadoptiveimmunotherapyforlymphomausingachimericantigenreceptorwithbothCD28and4-1BBdomains:pilotclinicaltrialresults

BrianG.Till,1,2MichaelC.Jensen,1,3JinjuanWang,1XiaojunQian,1AjayK.Gopal,1,2DavidG.Maloney,1,2

CatherineG.Lindgren,1YukangLin,1JohnM.Pagel,1,2LihuaE.Budde,1,2AndrewRaubitschek,4StephenJ.Forman,4PhilipD.Greenberg,1,2StanleyR.Riddell,1,2andOliverW.Press1,2

1Clinical3Seattle

ResearchDivision,FredHutchinsonCancerResearchCenter,Seattle,WA;2DepartmentofMedicine,UniversityofWashington,Seattle,WA;Children’sResearchInstitute,Seattle,WA;and4CityofHopeCancerResearchCenter,Duarte,CA

Cellularimmuneresponseshavethepo-tentialtoelicitdramaticandsustainedclinicalremissionsinlymphomapatients.Recentclinicaltrialdatademonstratethatmodi cationofTcellswithchimericantigenreceptors(CARs)isapromisingstrategy.TcellscontainingCARswithcostimulatorydomainsexhibitimprovedactivityagainsttumors.Weconductedapilotclinicaltrialtestinga“third-generation”CD20-speci cCARwithCD28and4-1BBcostimulatorydomainsinpatientswithrelapsedindolentB-cellandmantlecelllymphomas.Fourpa-tientswereenrolled,and3receivedT-cellinfusionsaftercyclophosphamidelym-phodepletion.Treatmentwaswelltoler-ated,althoughonepatientdevelopedtransientinfusionalsymptoms.Twopa-tientswithoutevaluablediseaseremainedprogression-freefor12and24months.Thethirdpatienthadanobjectivepartialremissionandrelapsedat12monthsafterinfusions.Modi edTcellsweredetectedbyquantitativePCRattumorsitesandupto1yearinperipheralblood,albeitatlow

levels.Noevidenceofhostimmunere-sponsesagainstinfusedcellswasdetected.Inconclusion,adoptiveimmunotherapywithCD20-speci cTcellswaswelltoleratedandwasassociatedwithantitumoractivity.WewillpursuealternativegenetransfertechnologiesandcultureconditionsinfuturestudiestoimproveCARexpressionandcellproductionef ciency.Thisstudyisregisteredatdoc.guandang.net.(Blood.2012;119(17):3940-3950)

Introduction

AdoptiveT-celltherapyhasemergedasapromisingstrategyforthetreatmentofcancer.1-7ThechallengesofisolatingTcellsreactivetowardtumor-associatedantigensandusingsuchcellsinpatientswithadiversityofhumanleukocyteantigen(HLA)phenotypeshave,tosomeextent,beenovercomethroughtheuseofchimericantigenreceptors(CARs).Thesegeneticallyengineeredmoleculestypicallyconsistofanextracellularantigen-bindingdomainde-rivedfromamonoclonalantibody(mAb),usuallyintheformofasingle-chainvariablefragment(scFv),linkedviaspacerandtransmembranedomainstoaT-cellsignalingendodomain,mostcommonlytheCD3 chain.8CAR-redirectedTcellshavethecapacitytorecognizecell-surfacetumortargetsinanHLA-independentfashion,leadingtoantigen-speci cTcellactivation,proliferation,andcytokineproduction,andthecapacitytoeradi-catetumorsinmousexenograftmodels.9-12

Non-Hodgkinlymphomas(NHLs),particularlytheindolentB-celllymphomasandmantlecelllymphoma(MCL),areappeal-ingtargetsforCAR-basedimmunotherapybecauseoftheirsus-ceptibilitytoTcell–mediatedimmuneeffects,asevidencedbylong-termremissionsafterallogeneicstemcelltransplantation(SCT).13,14TheCD20antigenonthesurfaceofB-NHLcellsisawell-establishedimmunotherapytargetforlymphoma,withnu-merousrandomizedtrialsdemonstratingimprovedclinicalout-comesinpatientstreatedwithanti-CD20Ab.

SubmittedOctober26,2011;acceptedJanuary13,2012.PrepublishedonlineasBloodFirstEditionpaper,February3,2012;DOI10.1182/blood-2011-10-387969.

ThereisanInsideBloodcommentaryonthisarticleinthisissue.Theonlineversionofthisarticlecontainsadatasupplement.

©2012byTheAmericanSocietyofHematology

Wepreviouslyreportedtheresultsofaphase1clinicaltrialinvestigatingtheuseofanti-CD20CAR autologousTcellstotreatpatientswithrelapsedindolentNHLandMCL.15Inthatstudy,wedemonstratedthesafetyandtolerabilityofthisapproachbutfoundthattheexvivoexpansionmethodsusedwereinef cientandthattheantitumoractivityandpersistenceofthemodi edTcellsweremodest.NumerouspreclinicalstudieshavedemonstratedthatCARsendowedwithco-stimulatoryendodomains,suchasCD28,OX40,or4-1BB(commonlyreferredtoas“secondgeneration”CARs),augmentT-cellactivitybothinvitroandinvivocomparedwith rst-generationCARslackingcostimulation.16-20TheseenhancedCARsweredesignedtomimicnormalphysiology,wherebothaprimaryTCRsignalandasecondcostimulatorysignalarerequiredforfullactivationofTcells.Thebene tofCARcostimulationwasrecentlycon rmedinaclinicaltrialinwhichaCD28-containingCARconferredsuperiorinvivoexpansionandpersistencecomparedwitha rst-generationCAR.21Potentantileukemicresponseswereseeninanotherrecenttrialinwhicha4-1BBdomainwasincorporatedintotheCAR.6Severalgroupshavecombined2costimulatorydomainsintotheCARconstructandshownsuperioractivityinpreclinicalstudies.22-24WepreviouslytestedmultipleCARcon gurationsinvitroandfoundthataCARcontainingCD28andCD137(4-1BB)domains

Thepublicationcostsofthisarticleweredefrayedinpartbypagechargepayment.Therefore,andsolelytoindicatethisfact,thisarticleisherebymarked‘‘advertisement’’inaccordancewith18USCsection1734.

3940

BLOOD,26APRIL2012 VOLUME119,NUMBER17

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email